CRISPR Genome Editing Accuracy: Framework 50 Achieves 80% Confidence Through Convergent Validation with CASGEVY Clinical Trial Correlation (93% Success Rate)
Bibliographic record
Abstract
BREAKTHROUGH: First computational framework achieving 80% confidence in CRISPR accuracy predictions through convergent validation—validated against FDA-approved CASGEVY gene therapy achieving 93% clinical success in sickle cell disease and β-thalassemia. FRAMEWORK 50 INNOVATIONIntegrates 39 computational modules implementing mathematical redundancy across three independent methodologies:• AlphaFold3-based structural prediction (pLDDT >85)• Published binding affinity data synthesis (850+ CRISPR fidelity studies)• Thermodynamic off-target screening When all three methods converge (Pearson r >0.90), error probability drops to <0.1%—below biological noise floor. CLINICAL VALIDATION• CLIMB-111 trial: 93% transfusion-independent β-thalassemia patients• CLIMB-121 trial: 93.5% VOC-free sickle cell patients• Framework 50 high-confidence predictions (r=0.91) aligned with 93% clinical success• Prime Medicine CGD study: 43-90% editing efficiency concordance CHECKPOINT ARCHITECTUREThree-layer systematic quality control:1. Computational prediction validity (inter-method correlation ≥0.85)2. Thermodynamic feasibility verification (ΔG ≥4 kcal/mol selectivity)3. Evolutionary conservation screening (off-targets in non-critical regions) Detected 100% of 30 documented poor-performance gRNA designs in validation testing. IMPACT FOR GENE THERAPY15+ CRISPR programs currently in clinical phases can optimize gRNA design using this framework, potentially reducing preclinical development timelines by 20-30% while improving design success rates and addressing FDA off-target concerns.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.026 | 0.066 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.002 | 0.001 |
| Open science | 0.002 | 0.002 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.009 | 0.004 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".